Cargando…

Clinical outcomes of temporal bone squamous cell carcinoma: A single‐institution experience

OBJECTIVES: This study aimed to investigate the survival outcomes and potential prognostic factors of patients with temporal bone squamous cell carcinoma (TBSCC) treated at our institution. METHODS: We retrospectively included patients who were diagnosed with TBSCC between 2008 and 2019. The Kaplan–...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yongbo, Qiu, Ke, Fu, Yangju, Yang, Wenjie, Cheng, Danni, Rao, Yufang, Mao, Minzi, Song, Yao, Xu, Wei, Ren, Jianjun, Zhao, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028158/
https://www.ncbi.nlm.nih.gov/pubmed/36229984
http://dx.doi.org/10.1002/cam4.5338
_version_ 1784909883005468672
author Zheng, Yongbo
Qiu, Ke
Fu, Yangju
Yang, Wenjie
Cheng, Danni
Rao, Yufang
Mao, Minzi
Song, Yao
Xu, Wei
Ren, Jianjun
Zhao, Yu
author_facet Zheng, Yongbo
Qiu, Ke
Fu, Yangju
Yang, Wenjie
Cheng, Danni
Rao, Yufang
Mao, Minzi
Song, Yao
Xu, Wei
Ren, Jianjun
Zhao, Yu
author_sort Zheng, Yongbo
collection PubMed
description OBJECTIVES: This study aimed to investigate the survival outcomes and potential prognostic factors of patients with temporal bone squamous cell carcinoma (TBSCC) treated at our institution. METHODS: We retrospectively included patients who were diagnosed with TBSCC between 2008 and 2019. The Kaplan–Meier (KM) method was used to describe overall survival (OS), and the association between baseline characteristics and prognoses was examined using Cox proportional hazards models. RESULTS: Fifty consecutive patients with TBSCC were included in this study. The results showed that patients with advanced modified Pittsburgh (MPB)‐ T classifications had a poorer prognosis (T3 vs. T1‐2: HR: 2.81, 95% CI: 0.34–23.43; T4 vs. T1‐2: HR: 7.25, 95% CI: 0.95–55.41; p = 0.041). Meanwhile, middle ear squamous cell carcinoma (MESCC) showed a significantly worse prognosis than external auditory canal squamous cell carcinoma (EACSCC, HR: 2.65, 95% CI: 1.04–6.76, p = 0.04). CONCLUSIONS: MESCC and advanced MPB‐T classifications might be considered predictors of unfavorable outcomes in patients with TBSCC, indicating that special attention should be paid to the original tumor subsite and tumor extension in the management of patients with TBSCC.
format Online
Article
Text
id pubmed-10028158
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100281582023-03-22 Clinical outcomes of temporal bone squamous cell carcinoma: A single‐institution experience Zheng, Yongbo Qiu, Ke Fu, Yangju Yang, Wenjie Cheng, Danni Rao, Yufang Mao, Minzi Song, Yao Xu, Wei Ren, Jianjun Zhao, Yu Cancer Med RESEARCH ARTICLES OBJECTIVES: This study aimed to investigate the survival outcomes and potential prognostic factors of patients with temporal bone squamous cell carcinoma (TBSCC) treated at our institution. METHODS: We retrospectively included patients who were diagnosed with TBSCC between 2008 and 2019. The Kaplan–Meier (KM) method was used to describe overall survival (OS), and the association between baseline characteristics and prognoses was examined using Cox proportional hazards models. RESULTS: Fifty consecutive patients with TBSCC were included in this study. The results showed that patients with advanced modified Pittsburgh (MPB)‐ T classifications had a poorer prognosis (T3 vs. T1‐2: HR: 2.81, 95% CI: 0.34–23.43; T4 vs. T1‐2: HR: 7.25, 95% CI: 0.95–55.41; p = 0.041). Meanwhile, middle ear squamous cell carcinoma (MESCC) showed a significantly worse prognosis than external auditory canal squamous cell carcinoma (EACSCC, HR: 2.65, 95% CI: 1.04–6.76, p = 0.04). CONCLUSIONS: MESCC and advanced MPB‐T classifications might be considered predictors of unfavorable outcomes in patients with TBSCC, indicating that special attention should be paid to the original tumor subsite and tumor extension in the management of patients with TBSCC. John Wiley and Sons Inc. 2022-10-13 /pmc/articles/PMC10028158/ /pubmed/36229984 http://dx.doi.org/10.1002/cam4.5338 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Zheng, Yongbo
Qiu, Ke
Fu, Yangju
Yang, Wenjie
Cheng, Danni
Rao, Yufang
Mao, Minzi
Song, Yao
Xu, Wei
Ren, Jianjun
Zhao, Yu
Clinical outcomes of temporal bone squamous cell carcinoma: A single‐institution experience
title Clinical outcomes of temporal bone squamous cell carcinoma: A single‐institution experience
title_full Clinical outcomes of temporal bone squamous cell carcinoma: A single‐institution experience
title_fullStr Clinical outcomes of temporal bone squamous cell carcinoma: A single‐institution experience
title_full_unstemmed Clinical outcomes of temporal bone squamous cell carcinoma: A single‐institution experience
title_short Clinical outcomes of temporal bone squamous cell carcinoma: A single‐institution experience
title_sort clinical outcomes of temporal bone squamous cell carcinoma: a single‐institution experience
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028158/
https://www.ncbi.nlm.nih.gov/pubmed/36229984
http://dx.doi.org/10.1002/cam4.5338
work_keys_str_mv AT zhengyongbo clinicaloutcomesoftemporalbonesquamouscellcarcinomaasingleinstitutionexperience
AT qiuke clinicaloutcomesoftemporalbonesquamouscellcarcinomaasingleinstitutionexperience
AT fuyangju clinicaloutcomesoftemporalbonesquamouscellcarcinomaasingleinstitutionexperience
AT yangwenjie clinicaloutcomesoftemporalbonesquamouscellcarcinomaasingleinstitutionexperience
AT chengdanni clinicaloutcomesoftemporalbonesquamouscellcarcinomaasingleinstitutionexperience
AT raoyufang clinicaloutcomesoftemporalbonesquamouscellcarcinomaasingleinstitutionexperience
AT maominzi clinicaloutcomesoftemporalbonesquamouscellcarcinomaasingleinstitutionexperience
AT songyao clinicaloutcomesoftemporalbonesquamouscellcarcinomaasingleinstitutionexperience
AT xuwei clinicaloutcomesoftemporalbonesquamouscellcarcinomaasingleinstitutionexperience
AT renjianjun clinicaloutcomesoftemporalbonesquamouscellcarcinomaasingleinstitutionexperience
AT zhaoyu clinicaloutcomesoftemporalbonesquamouscellcarcinomaasingleinstitutionexperience